Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied? - Archive ouverte HAL Access content directly
Journal Articles Antiviral Therapy Year : 2010

Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?

(1)
1

Abstract

The emergence of hepatitis B virus (HBV) drug-resistant (and multidrug-resistant) strains during long-term therapy with nucleoside/nucleotide analogues is associated with treatment failure and, therefore, represents a clinical challenge. For clinicians, the close monitoring and management of resistance has become a key issue in clinical practice. For HBV virologists, the understanding of the mechanism of emergence of specific mutant strains in the viral quasispecies during treatment is also an important issue. If a particular viral strain can emerge in the quasispecies within a particular environment, it is probably because its fitness is superior to other strains. The present review focuses on viral fitness as well as viral infectivity, and in particular on technical means that are available to study this viral fitness in vitro and in animal models.
Fichier principal
Vignette du fichier
Revised-Proceeding_Atlanta-DD.pdf (184.81 Ko) Télécharger le fichier
Vignette du fichier
Atlanta-2009-DD.ppt (5.57 Mo) Télécharger le fichier
Vignette du fichier
inserm-00490020_edited.pdf (141.52 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Format : Other
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00490020 , version 1 (07-06-2010)

Identifiers

Cite

David Durantel. Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?. Antiviral Therapy, 2010, 15 (3 Pt B), pp.521-7. ⟨10.3851/IMP1551⟩. ⟨inserm-00490020⟩
50 View
433 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More